Tamoxifen versus letrozole in combination with clomiphene citrate to stimulate ovulation in clomiphene-resistant PCOS women

Sowedan, Ibrahiem; Salama, Khalid M.; Shaer, Ossama El

doi:10.1097/01.ebx.0000471725.56003.7c

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our results, EL-Gharib and his colleagues who found that, there was no significant difference between both groups regarding age and BMI [11] . Sowedan and his colleagues also showed that, there was no significant difference between the studied groups concerning demographic data (age, BMI) [12] .…”

Section: Discussionmentioning

confidence: 86%

Letrozole Versus Tomoxifen in Infertile Woman with Clomiphene Citrate Resistant Polycystic Ovarian Syndrome

Saad,

Saleh,

Mahmoud El-Melih

et al. 2023

Evidence Based Women's Health Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 86%

Letrozole Versus Tomoxifen in Infertile Woman with Clomiphene Citrate Resistant Polycystic Ovarian Syndrome

Saad,

Saleh,

Mahmoud El-Melih

et al. 2023

Evidence Based Women's Health Journal

View full text Add to dashboard Cite

show abstract

“…Alitretinoin is also known as retinoic acid and derived from maternal vitamin A. Altered retinoic acid synthesis and action could influence the expression of these genes and androgen production in PCOS [63]. Tamoxifen, as one of the selective estrogen receptor modulators (SERM) with tissue-specific activities, is discovered to be a good alternative to clomiphene in women with PCOS and clomiphene-resistant case [64]. These durgs may play key roles in treating PCOS by multiple ways.…”

Section: Discussionmentioning

confidence: 99%

Identification of polycystic ovary syndrome potential drug targets based on pathobiological similarity in the protein-protein interaction network

Huang

Wan

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most common endocrinological disorders in reproductive aged women. PCOS and Type 2 Diabetes (T2D) are closely linked in multiple levels and possess high pathobiological similarity. Here, we put forward a new computational approach based on the pathobiological similarity to identify PCOS potential drug target modules (PPDT-Modules) and PCOS potential drug targets in the protein-protein interaction network (PPIN). From the systems level and biological background, 1 PPDT-Module and 22 PCOS potential drug targets were identified, 21 of which were verified by literatures to be associated with the pathogenesis of PCOS. 42 drugs targeting to 13 PCOS potential drug targets were investigated experimentally or clinically for PCOS. Evaluated by independent datasets, the whole PPDT-Module and 22 PCOS potential drug targets could not only reveal the drug response, but also distinguish the statuses between normal and disease. Our identified PPDT-Module and PCOS potential drug targets would shed light on the treatment of PCOS. And our approach would provide valuable insights to research on the pathogenesis and drug response of other diseases.

show abstract

Tamoxifen versus letrozole in combination with clomiphene citrate to stimulate ovulation in clomiphene-resistant PCOS women

Cited by 2 publications

References 21 publications

Letrozole Versus Tomoxifen in Infertile Woman with Clomiphene Citrate Resistant Polycystic Ovarian Syndrome

Letrozole Versus Tomoxifen in Infertile Woman with Clomiphene Citrate Resistant Polycystic Ovarian Syndrome

Identification of polycystic ovary syndrome potential drug targets based on pathobiological similarity in the protein-protein interaction network

Contact Info

Product

Resources

About